Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 4:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 920 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hepatitis C Virus (HCV) Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection

NCT02073656
View directory record Official record
Conditions
Hepatitis C Virus, HIV
Interventions
LDV/SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
34
States / cities
Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 14, 2026, 4:58 PM EDT
Completed Phase 4 Interventional Results available

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program.

NCT00087594
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
peginterferon alfa-2a [Pegasys], ribavirin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
7
States / cities
San Francisco, California • Farmington, Connecticut • Honolulu, Hawaii + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2016 · Synced Oct 14, 2026, 4:58 PM EDT
Terminated Not applicable Interventional Results available

Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients

NCT00871845
View directory record Official record
Conditions
Obesity, Insulin Resistance, Metabolic Syndrome, Hepatitis C
Interventions
Dietary and Lifestyle modification educational sessions
Behavioral
Lead sponsor
Hossam Kandil
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Oct 14, 2026, 4:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults

NCT01458054
View directory record Official record
Conditions
Hepatitis C
Interventions
Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose), Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 14, 2026, 4:58 PM EDT
Completed Phase 2 Interventional

The Effects of Mogroside Sweetener on Viral Load in TreatmenT Naive Genotype 1 (GT 1) Subjects CHC

NCT00926120
View directory record Official record
Conditions
Hepatitis C
Interventions
Mogroside sweetener (PureLo)
Dietary Supplement
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 14, 2026, 4:58 PM EDT
Completed No phase listed Observational

Patient Self-management and Gene Guided Therapy for Chronic Hepatitis C

NCT02006823
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Durham, North Carolina • Rocky Mount, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 15, 2014 · Synced Oct 14, 2026, 4:58 PM EDT
Completed Not applicable Interventional Results available

Nurse Case Management to Improve Hepatitis C Care in HIV Co-infection

NCT02707991
View directory record Official record
Conditions
HIV, Hepatitis C, Chronic
Interventions
Nurse Case Management
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced Oct 14, 2026, 4:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation

NCT01579162
View directory record Official record
Conditions
Hepatitis C, Chronic, Non-Alcoholic Fatty Liver Disease
Interventions
Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123)
Device
Lead sponsor
HepQuant, LLC
Industry
Eligibility
22 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 14, 2026, 4:58 PM EDT
Completed Phase 2 Interventional

A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection.

NCT00377182
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Copegus, PEGASYS, RO5024048 1500mg, RO5024048 3000mg
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
17
States / cities
La Jolla, California • Long Beach, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 14, 2026, 4:58 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Testing of a Navigation Intervention for Hepatitis C and HIV

NCT04499651
View directory record Official record
Conditions
HIV (Human Immunodeficiency Virus), Hepatitis C
Interventions
Navigation
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 14, 2026, 4:58 PM EDT
Completed Phase 1 Interventional

The Effects of IL-1 Blockade on Inotrope Sensitivity in Patients With Heart Failure (AID-HEART)

NCT06062966
View directory record Official record
Conditions
Heart Failure
Interventions
Anakinra
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 14, 2026, 4:58 PM EDT
Completed Phase 1 Interventional

A Pilot Study of the Grapefruit Flavonoid Naringenin for HCV Infection

NCT01091077
View directory record Official record
Conditions
Hepatitis C Virus, HCV Infection, Chronic HCV, Hepatitis C
Interventions
Naringenin
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Oct 14, 2026, 4:58 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans

NCT06766331
View directory record Official record
Conditions
Opioid Use Disorder, HIV, Hepatitis C Virus, Gonorrhea, Chlamydia, Syphilis, Sexually Transmitted Infection, Integrated Care, Medications for Opioid Use Disorder
Interventions
Integrated care
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2028 – 2029
U.S. locations
1
States / cities
Northport, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 14, 2026, 4:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TD-6450 SAD and MAD in Healthy Subjects

NCT02022306
View directory record Official record
Conditions
Hepatitis C
Interventions
TD-6450, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 60 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 14, 2026, 4:58 PM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Assessing Performance of a Hepatitis C Emergency Department (HepC-EnD) Screening Tool: IT Integration Process for Electronic Health Record System

NCT07406490
View directory record Official record
Conditions
Hepatitis C Virus (HCV), Hepatitis C Virus (HCV) Infection, HIV (Human Immunodeficiency Virus)
Interventions
Physician-Initiated Screening (Conventional Screening), FOCUS (Universal Screening), HepC-EnD (Targeted Screening)
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 79 Years
Enrollment
6,466 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
3
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 14, 2026, 4:58 PM EDT
Suspended Not applicable Interventional

Mucomyst for Hepatitis C

NCT00493610
View directory record Official record
Conditions
Hepatitis C
Interventions
N-acetylcysteine(Mucomyst)
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 8, 2010 · Synced Oct 14, 2026, 4:58 PM EDT
Completed No phase listed Observational

Zepatier in Patients with Substance Use

NCT04048850
View directory record Official record
Conditions
Hepatitis C, Hiv, Coinfection, HIV, Substance Use Disorders
Interventions
Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 14, 2026, 4:58 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C

NCT01821625
View directory record Official record
Conditions
Thrombocytopenia, Hepatitis C
Interventions
Eltrombopag
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 14, 2026, 4:58 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study of High Dosage CIFN Plus RBV for HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Therapy

NCT00266318
View directory record Official record
Conditions
Hepatitis C
Interventions
Interferon Alfacon-1 and Ribavirin
Drug
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2008 · Synced Oct 14, 2026, 4:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients

NCT01523990
View directory record Official record
Conditions
Healthy, Hepatitis C, Chronic
Interventions
TG-2349, placebo
Drug
Lead sponsor
TaiGen Biotechnology Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 14, 2026, 4:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl in Patients With Chronic Hepatitis C

NCT02118012
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Chlorcyclizine HCl, Ribavirin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 14, 2026, 4:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Behavioral Science Aspects of Rapid Test Acceptance

NCT01317784
View directory record Official record
Conditions
HIV, Hepatitis C, Hepatitis B, Syphilis
Interventions
Rapid tests for HIV, HCV, HBV, and syphilis, HIV/HCV, HIV/syphilis, HIV only
Device
Lead sponsor
California State University, Long Beach
Other
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2015 · Synced Oct 14, 2026, 4:58 PM EDT
Completed Not applicable Interventional Results available

TeleHepC Treatment Trial

NCT04798521
View directory record Official record
Conditions
Hepatitis C
Interventions
Tele-HCV, Community Linkage to Care
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Portland, Oregon • Roseburg, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 14, 2026, 4:58 PM EDT
Terminated No phase listed Observational

A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials

NCT02510300
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
Sofosbuvir (SOF), Ledipasvir/Sofosbuvir (LDV/SOF), Sofosbuvir/Velpatasvir (SOF/VEL), Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
3 Years and older
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
27
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2023 · Synced Oct 14, 2026, 4:58 PM EDT